ARTICLE 1 DEFINITIONS AND INCORPORATION BY REFERENCEIndenture • January 12th, 2001 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations • New York
OFAgreement • November 14th, 2000 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations • California
BETWEENStock Purchase Agreement • December 14th, 1998 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations • California
AGREEMENT FOR THE CONTRIBUTION OF THE 201 INDUSTRIAL ROAD PROJECT SAN CARLOS, CALIFORNIAContribution Agreement • November 14th, 2000 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations • California
STATEMENT OF ELIGIBILITY AND QUALIFICATION UNDER THE TRUST INDENTURE ACT OF 1939 OF A CORPORATION DESIGNATED TO ACT AS TRUSTEE ------------------------ CHECK IF AN APPLICATION TO DETERMINE ELIGIBILITY OF A TRUSTEE PURSUANT TO SECTION...Inhale Therapeutic Systems Inc • May 2nd, 2000 • Pharmaceutical preparations
PRE-FUNDED COMMON STOCK PURCHASE WARRANT NEKTAR THERAPEUTICSNektar Therapeutics • March 4th, 2024 • Pharmaceutical preparations
This Warrant is issued pursuant to that certain Securities Purchase Agreement, dated March [ ], 2024, by and among the Company and the Purchaser identified therein (the “Purchase Agreement”). This Warrant and all new warrants, if any, issued by the Company pursuant to Section 4 hereof are referred to herein, collectively, as the “Warrants.”
19,000,000 Shares NEKTAR THERAPEUTICS Common Stock ($0.0001 par value per Share) UNDERWRITING AGREEMENTUnderwriting Agreement • January 21st, 2011 • Nektar Therapeutics • Pharmaceutical preparations • New York
AMENDMENT TO LEASELease • November 14th, 2000 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations
LANDLORD ANDInhale Therapeutic Systems Inc • November 14th, 2000 • Pharmaceutical preparations • California
NEKTAR THERAPEUTICS 13,000,000 Shares of Common Stock, $0.0001 par value per share Underwriting AgreementNektar Therapeutics • October 19th, 2016 • Pharmaceutical preparations • New York
Nektar Therapeutics, a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 13,000,000 shares of Common Stock, par value $0.0001 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional 1,950,000 shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
NEKTAR THERAPEUTICS, Issuer AND J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION, TrusteeIndenture • September 17th, 2003 • Nektar Therapeutics • Pharmaceutical preparations • New York
INDENTURE, dated as of [ • ], 2003, among NEKTAR THERAPEUTICS, a Delaware corporation (the "Company"), and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION, as trustee (the "Trustee"):
RECITALSAmendment Agreement • August 16th, 1999 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations
LETTERHEAD] INHALEInhale Therapeutic Systems Inc • March 10th, 2000 • Pharmaceutical preparations • California
3 1/2% Convertible Subordinated Notes due 2007 PURCHASE AGREEMENTInhale Therapeutic Systems Inc • January 12th, 2001 • Pharmaceutical preparations • New York
PURCHASE AGREEMENTPurchase Agreement • January 31st, 1997 • Inhale Therapeutic Systems • Pharmaceutical preparations • New York
AGREEMENT AND PLAN OF MERGER THIS AGREEMENT AND PLAN OF MERGER (hereinafter called the "Merger Agreement") is made as of June 4, 1998, by and between INHALE THERAPEUTIC SYSTEMS, a California corporation ("Inhale California"), and INHALE THERAPEUTIC...Agreement and Plan of Merger • August 13th, 1998 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations
AND BRADFORD PARTICLE DESIGN PLC AGREEMENT GRANTING AN ENTERPRISE MANAGEMENT INCENTIVES OPTION THIS AGREEMENT is made the day of 2000 BETWEEN (1) ________________ of __________________________ ("THE OPTIONHOLDER"); (2) BRADFORD PARTICLE DESIGN PLC...Exhibit 99 • February 6th, 2001 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations
NEKTAR THERAPEUTICS COMMON STOCK SALES AGREEMENTSales Agreement • March 12th, 2021 • Nektar Therapeutics • Pharmaceutical preparations • New York
Dated October 27, 2000Agreement • February 6th, 2001 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations
AMONGManufacturing and Supply Agreement • March 1st, 2001 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations • California
INHALE THERAPEUTIC SYSTEMS, INC. 6 3/4% CONVERTIBLE SUBORDINATED DEBENTURES DUE 2006 PURCHASE AGREEMENTInhale Therapeutic Systems Inc • January 6th, 2000 • Pharmaceutical preparations • New York
NEKTAR THERAPEUTICS, Issuer AND J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION, TrusteeNektar Therapeutics • October 27th, 2004 • Pharmaceutical preparations • New York
INDENTURE, dated as of [ • ], among NEKTAR THERAPEUTICS, a Delaware corporation (the "Company"), and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION, as trustee (the "Trustee"):
Exhibit 4.17 RESALE REGISTRATION RIGHTS AGREEMENTResale Registration Rights Agreement • January 12th, 2001 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations • New York
Exhibit I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the...Joint Filing Agreement • February 3rd, 2004 • Nektar Therapeutics • Pharmaceutical preparations
This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, $0.0001 par value, of Nektar Therapeutics, a Delaware corporation, is being filed, and all amendments thereto will be filed, on behalf of each of the persons and entities named below in accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
200,000,000 5.00% Convertible Subordinated Notes due 2007Inhale Therapeutic Systems Inc • March 10th, 2000 • Pharmaceutical preparations
EXHIBIT 99.2 INHALE THERAPEUTIC SYSTEMS, INC. 2000 NON-OFFICER EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT (NONSTATUTORY STOCK OPTION) Pursuant to the Nonstatutory Stock Option Notice ("Option Notice") and this Stock Option Agreement, Inhale...Stock Option Agreement • January 19th, 2001 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations
May 13, 2008Nektar Therapeutics • May 22nd, 2008 • Pharmaceutical preparations
INDENTURE between NEKTAR THERAPEUTICS, as Issuer and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION as Trustee 3.25% CONVERTIBLE SUBORDINATED NOTES DUE 2012 Dated as of September 28, 2005Indenture • September 28th, 2005 • Nektar Therapeutics • Pharmaceutical preparations • New York
INDENTURE, dated as of September 28, 2005, between NEKTAR THERAPEUTICS, a corporation duly organized and existing under the laws of the State of Delaware, having its principal office at 150 Industrial Road, San Carlos, California 94070 (the “Company”), and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION, a national banking association, as Trustee (the “Trustee”), having its principal corporate trust office at 600 Travis Street, Suite 1150, Houston, Texas 77002.
PLEDGE AGREEMENTPledge Agreement • November 3rd, 2003 • Nektar Therapeutics • Pharmaceutical preparations • New York
This PLEDGE AGREEMENT (this “Agreement”) is made and entered into as of October 9, 2003 by and among NEKTAR THERAPEUTICS, a Delaware corporation (the “Grantor”), having its principal executive offices at 150 Industrial Road, San Carlos, California 94070 and J.P. MORGAN TRUST COMPANY, NATIONAL ASSOCIATION (“J.P. Morgan”), having an office at 560 Mission Street, 13th Floor, San Francisco, California 94105, (i) in its capacity as trustee (the “Trustee”) for the holders (the “Holders”) of the Notes (as hereinafter defined) issued by the Grantor under the Indenture referred to below and (ii) in its individual capacity, as securities intermediary (in such capacity, the “Pledged Securities Intermediary”) at its office in New York c/o: J.P. Morgan Chase Bank, Institutional Trust Services, 4 New York Plaza, 15th Floor, New York, New York 10004 (the “Account Office”) with respect to the Pledge Account (as hereinafter defined). Capitalized terms used herein and not otherwise defined herein shall
CONFIDENTIAL CONSULTING AGREEMENTConfidential Consulting Agreement • May 10th, 2023 • Nektar Therapeutics • Pharmaceutical preparations
This Confidential Consulting Agreement (the “Agreement”) is executed as of the date shown on the signature page (the “Effective Date”), by and between FLG Partners, LLC, a California limited liability company (“FLG”), and Nektar Therapeutics, a Delaware company, with its principal place of business at 455 Mission Bay Boulevard South, Suite 100, San Francisco, California 94158 (“Client”).
EXCHANGE AGREEMENTExchange Agreement • November 3rd, 2003 • Nektar Therapeutics • Pharmaceutical preparations • New York
This EXCHANGE AGREEMENT (the “Agreement”) is made and entered into as of October 30, 2003, by and between NEKTAR THERAPEUTICS, a Delaware corporation (the “Company”) and the entities set forth on Appendix I hereto (each a “Holder” and collectively the “Holders”).
OFFICE LEASEOffice Lease • August 9th, 2018 • Nektar Therapeutics • Pharmaceutical preparations • California
This Office Lease (the "Lease"), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the "Summary"), below, is made by and between KILROY REALTY FINANCE PARTNERSHIP, L.P., a Delaware limited partnership ("Landlord"), and NEKTAR THERAPEUTICS, a Delaware corporation ("Tenant").
NEKTAR THERAPEUTICS SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 4th, 2024 • Nektar Therapeutics • Pharmaceutical preparations • New York
THIS SECURITIES PURCHASE AGREEMENT (the “Agreement”) is made as of March 4, 2024 (the “Effective Date”), by and between NEKTAR THERAPEUTICS, a Delaware corporation (the “Company”), and TCG Crossover Fund II, L.P., a Delaware limited partnership (the “Purchaser”).
ANDRights Agreement • June 4th, 2001 • Inhale Therapeutic Systems Inc • Pharmaceutical preparations • New York
PLEDGE AND SECURITY AGREEMENTPledge and Security Agreement • October 6th, 2015 • Nektar Therapeutics • Pharmaceutical preparations • New York
THIS PLEDGE AND SECURITY AGREEMENT (this “Agreement”) is made as of October 5, 2015, by Nektar Therapeutics, a corporation organized under the laws of the State of Delaware (the “Company”), and the subsidiaries of the Company that become guarantors hereunder pursuant to Section 10(o) hereof (together with the Company, the “Grantors” and each one a “Grantor”), whose principal place of business and chief executive office (as those terms are used in the Uniform Commercial Code of the State of New York (the “New York UCC”)) are set forth beneath their corresponding signature pages hereto, in favor of TC Lending, LLC, not in its individual capacity but solely as collateral agent (together with its successors and assigns, in such capacity “Collateral Agent”), for the benefit of the Secured Parties (as hereinafter defined), to secure the Notes, the Note Guarantees and all other Obligations under the other Indenture Documents. The Grantors hereby agree with Collateral Agent as follows:
